<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="107551">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01862263</url>
  </required_header>
  <id_info>
    <org_study_id>CLAF237AMX01</org_study_id>
    <nct_id>NCT01862263</nct_id>
  </id_info>
  <brief_title>Effect of 13-Week Treatment With Vildagliptin as Add-On Therapy to Improve Glucose Variability in Type II Diabetes</brief_title>
  <acronym>VIDA</acronym>
  <official_title>A Multicenter, Double-Blind, Randomized, Parallel-Group Placebo-Controlled Study to Compare the Effect of 13-Week Treatment With Vildagliptin as Add-On Therapy to Improve Glucose Variability in Type 2 Diabetes Mellitus Patients Inadequately Controlled With Insulin.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <authority>Mexico: Mexican Ministry of Health</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to assess if the addition of vildagliptin as add-on therapy
      improves glucose variability in type 2 diabetes mellitus (T2DM) patients inadequately
      controlled with insulin, with special emphasis in hypoglycemic episodes measured by
      continuous glucose monitoring.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Anticipated">October 2014</completion_date>
  <primary_completion_date type="Anticipated">October 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Percentage of patients with hyperglycemic events evaluated with CGM</measure>
    <time_frame>At 13 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>An hypoglycemic event is defined as any continuous glucose monitoring (CGM) measurement less than 60 mg/dL and a hyperglycemic is define as any CGM greater than 140 mg/dL.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of hypoglycemia and/or hyperglycemia measured by CGM</measure>
    <time_frame>13 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>An episode of hypoglycemia is defined as any value of glucose under 60 mg/dL, an episode of hyperglycemia is defined as any value of glucose above 140mg/dL measured by CGM.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the curve (AUC 0-24) of the excursions of glucose values below 60 mg/dl per day</measure>
    <time_frame>0 to 24 hours daily for week 1, 4 and 13</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Duration and intensity of hypoglycemic episodes, measured as area under the curve (AUC 0-24) of the excursions of glucose values below 60 mg/dl per day, measured by continuous glucose monitoring</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average of insulin units per day administered during the study</measure>
    <time_frame>13 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Change from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from the baseline in Lipid Profile</measure>
    <time_frame>Baseline, 13 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Lipid Profile will include total cholesterol, HDL cholesterol, LDL cholesterol, VLDL cholesterol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Body weight</measure>
    <time_frame>Baseline, 13 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Weight will be measured on Kg.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Blood pressure (BP),</measure>
    <time_frame>Baseline, 13 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>BP will be mesured on mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Fasting plasma glucose (FPG),</measure>
    <time_frame>Baseline, 13 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>FPG will be measured on mg/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Hemoglobin A1C (HbA1c)</measure>
    <time_frame>Baseline, 13 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>HbA1c will be measured on %</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Creatinine</measure>
    <time_frame>Baseline, 13 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Creatinine will be measured on mg/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in C-peptide</measure>
    <time_frame>Baseline, 13 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>C-Peptide will be measured on microIU/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in alanine aminotransferase (ALT)/aspartate aminotransferase (AST)</measure>
    <time_frame>Baseline, 13 week</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>ALT/AST will be measured on ratio.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in Direct bilirubin</measure>
    <time_frame>Baseline, 13 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Bilirubin will be measure on mg/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in Body Mass Index (BMI)</measure>
    <time_frame>Baseline, 13 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with adverse events, serious adverse events and death as evaluation of safety and tolerability of coadministration of vildagliptin with insulin</measure>
    <time_frame>13 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">238</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Vildagliptin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vildagliptin  50 mg twice daily (bid) + Insulin 20 to 40 IU/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Insulin 20 to 40 IU/day + Vildagliptin Placebo twice daily (bid)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vildagliptin</intervention_name>
    <description>Orally active and highly selective inhibitor of DPP-4</description>
    <arm_group_label>Vildagliptin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin</intervention_name>
    <description>Long- acting human insulin analog indicated to improve glycemic control</description>
    <arm_group_label>Vildagliptin</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo of vildagliptin</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Informed consent read and signed before any protocol procedure.

          2. Free will to sign the informed consent.

          3. Male and female between 18 and 80 years. If female, patient must be non-fertile or of
             childbearing potential using a medically approved birth control method.

          4. Type 2 diabetes mellitus

          5. Patient under insulin treatment within 3 years with stable insulin NPH (Neutral
             ProtamineHagedorn) regimen at dose of at least 20 UI/day up to 40 UI/day for a
             minimum of 4 weeks prior to enrolment, only NPH and glargine insulin are allowed.

          6. HbA1c between 7.5 to 9%.

          7. Fasting plasma glucose (FPG) less than 270 mg/dL.

          8. Body mass index (BMI) between 20 to 35 kg/m2.

          9. Free willing to take the vildagliptin tablets during the study.

        Exclusion Criteria

          1. Pregnant or lactating female or without birth control method if of childbearing
             potential.

          2. Type 1 diabetes, diabetes that is a result of pancreatic injury, or secondary forms
             of diabetes, e.g., Cushing's syndrome.

          3. Acute cardiovascular complications or metabolic complications within the past 4
             months.

          4. History cerebrovascular disease during the last year.

          5. History of Torsades de Points, ventricular tachycardia or ventricular fibrillation.

          6. Ischemic heart disease (e.g. myocardial infarction, unstable angina, coronary artery
             bypass surgery).

          7. Congestive heart failure requiring pharmacologic treatment.

          8. Any known serious heart condition.

          9. ALT and/or AST greater than three times the upper limit of the normal range.

         10. Serum creatinine levels greater than 1.5 mg/dL

         11. Malignancy including leukemia and lymphoma within the last 5 years

        Other inlcusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+41613241111</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ciudad De Mexico</city>
        <state>Distrito Federal</state>
        <zip>11850</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ciudad De Mexico</city>
        <state>Distrito Federal</state>
        <zip>06600</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mexico</city>
        <state>Distrito Federal</state>
        <zip>06700</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mexico</city>
        <state>Distrito Federal</state>
        <zip>07300</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mexico</city>
        <state>Distrito Federal</state>
        <zip>14050</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Metepec</city>
        <state>Edo. de México</state>
        <zip>52140</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Celaya</city>
        <state>Guanajuato</state>
        <zip>38 000</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>44150</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>44600</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>44670</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Guadaljara</city>
        <state>Jalisco</state>
        <zip>44140</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Monterrey</city>
        <state>Nuevo Leon</state>
        <zip>64710</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cadereyta Jimenez</city>
        <state>Nuevo León</state>
        <zip>67450</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Monterrey</city>
        <state>Nuevo León</state>
        <zip>64020</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Monterrey</city>
        <state>Nuevo León</state>
        <zip>64460</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cancun</city>
        <state>Quintana Roo</state>
        <zip>77506</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Culiacán</city>
        <state>Sinaloa</state>
        <zip>80000</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Matamoros</city>
        <state>Tamaulipas</state>
        <zip>87300</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Merida</city>
        <state>Yucatán</state>
        <zip>97133</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Puebla</city>
        <zip>72190</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <lastchanged_date>June 2, 2014</lastchanged_date>
  <firstreceived_date>May 22, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetes,</keyword>
  <keyword>Type 2 diabetes,</keyword>
  <keyword>Diabetes mellitus,</keyword>
  <keyword>insulin,</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Vildagliptin</mesh_term>
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
